Denis Collins is a translational research scientist and Principal Investigator of the Cancer Biotherapeutics group based at the NICB, Dublin City University.

The ultimate aim of Cancer Biotherapeutics group is to improve patient outcomes by getting novel treatment strategies to clinical trial.

Denis has a degree in Biochemistry from University College Cork. He graduated from DCU with his PhD on drug resistance in lung cancer in 2008. Since then, Denis has been awarded an Irish Research Council Enterprise Partnership Scheme Postdoctoral Fellowship and a Roche Postdoctoral Fellowship to support his research. He is a past Chair of the Junior Council of the Irish Association for Cancer Research (IACR) and is presently a member of the IACR Senior Council.

Denis is currently The Caroline Foundation Senior Research Fellow and Co-PI on a Science Foundation Ireland Strategic Partnership Programme Award, ACORN, that is studying the potential of small molecule tyrosine kinase inhibitors as treatments in multiple cancer types including breast, lung, gastric, oesophageal and skin cancer.

His research team is also funded by the Cancer Clinical Research Trust and the Irish Research Council. These studies investigate new antibody drug conjugate combinations and the immune response mediated by NK cells and monoclonal antibody therapies in breast cancer. Immune-based biomarker studies using patient blood and tumour are underway in lung, breast, gastric/oesophageal and skin cancers.